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Introduction
•

•

•

The topic was selected to educate health
care professionals on the complex
pathophysiological process of chronic
inflammatory demyelinating
polyneuropathy (CIDP).
CIDP is an autoimmune disease of the
peripheral nervous system in which the
myelin sheath surrounding nerves is
attacked, leading to improper conduction
of nerve impulses to peripheral nerves
(Greer & Wolf, 2015).

Regardless of clinical course, initial
presentation is nonspecific and gradual
(Alabdali et al., 2017, p.223).

•

Progressive course: unrelenting
progression of symptoms with limited to
no improvement or stabilization.

•

Relapsing-remitting course: periods of
exacerbations with increased symptoms
accompanied by periods of remission.

•

Monophasic: one occurrence of symptoms
that is treated and resolves (van Shaik et
al., 2016, p. 3).

•

Multiple sources debate whether CIDP is
over or under-diagnosed, but prevalence
is currently estimated at 1 to 2 per
100,000 adults (Reynolds, Sachs &
Stavros, 2016, p.32).

•

•

•

A male between 40 and 60 years of age noticed gradual onset of bilateral
weakness of his lower extremities, then numbness, and lastly difficulty
walking over the course of several months.

•

He presented to his physician, who performed a thorough neurological
assessment and nerve conduction studies (NCS). His physician also
completed an MRI and spinal tap to rule out other potential diagnoses.
After obtaining test results, his physician confirmed his diagnosis of CIDP.
(Kang et al., 2013, p.1-2)

•

He was initially treated with steroids, but did not show improvement, so he
was started on a maintenance therapy of IVIG every three weeks.

There are three courses CIDP can take;
progressive, relapsing-remitting, or
monophasic (Schaik et al., 2016, p.2).

•

CIDP is more common in males than
females, and is most commonly diagnosed
between ages 40-60 (Reynolds, Sachs &
Stavros, 2016, p.32-33).
CIDP has treatments available, but not all
courses of disease may be corrected with
available treatments, and progressive
accumulation of disability may occur (van
Shaik et al., 2016, p. 3).
The majority of patients with CIDP require
long-term management and treatment
(van Shaik et al., 2016, p. 3).

Pathophysiology of CIDP

Presentation of Case
•

CIDP symptoms are a result of
immune-mediated destruction of
peripheral nerves.

•

•

Acts on both the cellular and the
humoral pathways of the immune
system.

•

•

“Activated T lymphocytes invade
the peripheral nervous system
through derangement of the blood
brain barrier. Once within the
peripheral nervous system these
activated T cells generate proinflammatory cytokines and
produce cytotoxic activity against
myelin” (Reynolds, Sachs & Stavros,
2016, p.32).

•

Figures 2 & 3: Myelinated Nerve Fiber & Nerve Fiber Demyelination
Retrived from: GBS/CIDP Foundation International. (2018). CIDP chronic
inflammatory demyelinating polyneuropathy. GBS/CIDP Foundation
International. Retrieved from https://www.gbs-cidp.org/support/foundationpublications/

Signs & Symptoms
•

CIDP creates neurological disability which sometimes leads to decreased
functional status and decreased quality of life (Alabdali et al., 2017, p.223).

•

Diagnosis of CIDP is based on thorough history and neurological
assessment, as well as the presence of demyelination on nerve conduction
studies (Alabdali et al., 2017, p.224).

•

Cerebral spinal fluid will show elevated protein levels, and MRI imaging will
show enhanced nerve roots (Alabdali et al., 2017, p.224).

•

Symptoms present in three categories, sensory, motor, and autonomic
dysfunction (Alabdali et al., 2017, p.223).

•

Motor symptoms typically present first and include weakness, especially in
lower limbs, loss of deep tendon reflexes, unsteady gait, and fatigue.

•

Sensory symptoms include numbness, paresthesia in a “stocking-glove”
pattern, diminished sensation, and burning sensations (Reynolds, Sachs &
Stavros, 2016, p.32-34).

•

Autonomic dysfunction related to CIDP was previously thought to be rare,
but one study showed up to 86% of patients with CIDP experience
autonomic dysfunction (Pasangulapati, 2017, p. 276).

•

Autonomic symptoms include orthostatic hypotension, exercise intolerance,
palpitations, dizziness, weakness, and vision disturbances (Adamec et al.,
2016, p.1163).

•

Characterized by a slow progression of symptoms that reaches its peak
greater than 2 months after symptom onset (Ripellino, Fleetwood, Cantello,
& Cristoforo, 2014).

Significance of
Pathophysiology

Underlying
Pathophysiology

•

T cells are the main antagonists of
myelin sheath with “T cells,
especially T helper 1 (Th1) and T
helper 17 (Th17) on one side and T
regulatory (T reg) on the other”
(Ripellino et al., 2014).

•

While pathogenesis is not fully
understood, macrophages,
cytokines, and complement are also
involved in degradation of myelin
(Ripellino et al., 2014).

•

Immune response potentially
targets antigens on peripheral
nerves, such as myelin protein zero,
myelin basic protein, connexin 32,
and gangliosides (Reynolds, Sachs
& Stavros, 2016, p.32-33)

•

Activated T cells survive apoptosis
as a result of an altered Fas
pathway function (Ripellino et al.,
2014).

•

“The myelin sheath is composed of
various proteins, such as myelin
protein zero, which account for
more than 50 percent of the total
membrane protein in human
peripheral nervous system myelin”
(Köller et al., 2003).

•

•

It is likely that many subtypes of
CIDP exist (Reynolds, Sachs &
Stavros, 2016, p.32).
More research is needed to pinpoint
the exact antigens targeted in CIDP,
specifically for each subtype of CIDP
(Reynolds, Sachs & Stavros, 2016,
p.32).
Approximately 70% of patients
respond to immunomodulation
therapy, but as patients have
different subtypes, some patients
are difficult to treat and research
pinpointing specific proteins linked
to CIDP is necessary (Ripellino et al.,
2014).
In the future, treatments may be
specifically designed for patients on
a case by case basis after
identification of the pretense of
specific proteins such as CNTN1 and
NF155 (Reynolds, Sachs & Stavros,
2016, p.34).

Treatment
Pharmacological
immunosuppression with
medications such as azathioprine,
methotrexate, and
cyclophosphamide (Ripellino et al.,
2014).

•

Implications for
Nursing Care
•

Complete thorough neurological
assessments.

•

Involve physical and occupational
therapy in management of
weakness and sensation
abnormalities and the impact of
symptoms on activities of daily
living.

•

Intravenous or subcutaneous
immunoglobulin administered
approximately every three weeks
(van Shaik et al., 2016, p. 3).

•

Intravenous or oral steroids (van
Shaik et al., 2016, p. 3).

•

Educate patient and family
members on CIDP.

•

70% of patients respond to
immunotherapy (Ripellino,
Fleetwood, Cantello, & Cristoforo,
2014).

•

Encourage a healthy and wellbalanced diet

•

Monitor progression of disease
process (GBS/CIDP Foundation
International, 2018).

Conclusion
•

CIDP is a complex autoimmune demyelinating disorder that commonly
impacts patient’s quality of life and activities of daily living (Alabdali et al.,
2017, p.224).

•

More research is needed to improve diagnosis and treatments for specific
subtypes of CIDP, which will improve patient outcomes (Ripellino et al.,
2014).

Figure 3: Immunopathogenesis of CIDP
Retrived from: Köller, H., Kieseier, B.C., Jander, S., & Hartung, H.C. (2003). Chronic inflammatory
demyelinating polyneuropathy. The New England journal of medicine, 352 13, 1343-56.
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